Why it matters: PPTA’s Q2 2025 lobbying comes at a critical juncture. CMS is implementing Medicare Prescription Drug Inflation Rebate Program rules. The trade association maintains in-house lobbying rather than hiring external firms. This gives them direct control and specialized expertise in plasma therapeutics.
By the Numbers: PPTA spent $125,000 on lobbying activities in Q2 2025. The organization has invested $525,000 total over the past 12 months. Their three-person in-house team includes Anita Brikman, Sharon Scribner Pearce, and Daniel Seaton. PPTA conducts all lobbying internally without external firm assistance.
Why Now: Multiple policy threats are converging on the plasma therapeutics industry. CMS issued proposed Medicare Prescription Drug Inflation Rebate Program rules in mid-2025. Global plasma supply chain disruptions are creating additional pressures. Medicare Part B premiums increased 5.9% to $185 monthly in 2025. Hospital demand for blood products is rising after a decade of stability.
The Agenda: PPTA focuses on four key areas this quarter. Medicare Part B provisions for home infusion of IVIG top the list. CMS reference pricing systems present another concern. Source plasma donation and plasma protein product issues require attention. The Inflation Reduction Act provisions on plasma-derived therapies drive much advocacy. PPTA specifically supports HR 6465, The PLASMA Act. They also lobby on HR 3808 for Medicare mental health access.
Competitive Landscape: No specific competitive lobbying data was available for this quarter. PPTA represents companies developing plasma protein therapies for rare diseases. These life-saving medicines treat Primary Immunodeficiencies and CIDP. Alternative therapies are often unavailable for these conditions.
Between The Lines: The PLASMA Act faces a critical legislative window. Bipartisan support includes Rep. Richard Hudson (R-NC) and Sen. Thom Tillis (R-NC). The legislation would phase in rebate requirements starting 2026. Full implementation wouldn’t occur until 2031. Rep. Adrian Smith’s Medicare IVIG Access Enhancement Act supports PPTA’s home infusion priorities. Rep. María Salazar’s John W. Walsh Alpha-1 Home Infusion Act addresses similar access issues.
The Bottom Line: PPTA’s lobbying reflects urgent policy implementation deadlines. The Inflation Reduction Act’s drug pricing provisions threaten plasma therapeutics economics. Without legislative fixes, patient access to these essential treatments could suffer. The organization’s sustained advocacy demonstrates the industry’s recognition of these risks.
Spot something wrong? Report an issue with this article